Validation of standards for quantitative assessment of JAK2 c.1849G>T (p.V617F) allele burden analysis in clinical samples.
about
Monitoring Minimal Residual Disease in the Myeloproliferative Neoplasms: Current Applications and Emerging ApproachesPrimary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis.The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis.Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study.
P2860
Validation of standards for quantitative assessment of JAK2 c.1849G>T (p.V617F) allele burden analysis in clinical samples.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Validation of standards for qu ...... analysis in clinical samples.
@en
Validation of standards for quantitative assessment of JAK2 c.1849G>T
@nl
type
label
Validation of standards for qu ...... analysis in clinical samples.
@en
Validation of standards for quantitative assessment of JAK2 c.1849G>T
@nl
prefLabel
Validation of standards for qu ...... analysis in clinical samples.
@en
Validation of standards for quantitative assessment of JAK2 c.1849G>T
@nl
P2093
P2860
P356
P1476
Validation of standards for qu ...... analysis in clinical samples.
@en
P2093
Gregory Hollis
Keyur Patel
Mark Rupar
Paul Collier
Paul Waeltz
Phillip C C Liu
Rajyalakshmi Luthra
Reid Huber
Timothy C Burn
P2860
P304
P356
10.1089/GTMB.2012.0366
P577
2013-03-28T00:00:00Z